Your browser doesn't support javascript.
loading
Leptin Reduction as a Required Component for Weight Loss.
Zhao, Shangang; Li, Na; Xiong, Wei; Li, Guannan; He, Sijia; Zhang, Zhuzhen; Zhu, Qingzhang; Jiang, Nisi; Ikejiofor, Christian; Zhu, Yi; Wang, May-Yun; Han, Xianlin; Zhang, Ningyang; Solis-Herrera, Carolina; Kusminski, Christine; An, Zhiqiang; Elmquist, Joel K; Scherer, Philipp E.
Afiliación
  • Zhao S; Touchstone Diabetes Center, The University of Texas Southwestern Medical Center, Dallas, TX.
  • Li N; Division of Endocrinology, Department of Medicine, University of Texas Health Science Center, San Antonio, TX.
  • Xiong W; Sam and Ann Barshop Institute for Longevity and Aging Studies, University of Texas Health Science Center, San Antonio, TX.
  • Li G; Touchstone Diabetes Center, The University of Texas Southwestern Medical Center, Dallas, TX.
  • He S; Department of Endocrinology and Metabolism, Tianjin Medical University General Hospital, Tianjin, China.
  • Zhang Z; Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center at Houston, Houston, TX.
  • Zhu Q; Sam and Ann Barshop Institute for Longevity and Aging Studies, University of Texas Health Science Center, San Antonio, TX.
  • Jiang N; Sam and Ann Barshop Institute for Longevity and Aging Studies, University of Texas Health Science Center, San Antonio, TX.
  • Ikejiofor C; College of Life Sciences, Wuhan University, Wuhan, China.
  • Zhu Y; Touchstone Diabetes Center, The University of Texas Southwestern Medical Center, Dallas, TX.
  • Wang MY; Sam and Ann Barshop Institute for Longevity and Aging Studies, University of Texas Health Science Center, San Antonio, TX.
  • Han X; Sam and Ann Barshop Institute for Longevity and Aging Studies, University of Texas Health Science Center, San Antonio, TX.
  • Zhang N; Children's Nutrition Research Center, Department of Pediatrics, Baylor College of Medicine, Houston, TX.
  • Solis-Herrera C; Touchstone Diabetes Center, The University of Texas Southwestern Medical Center, Dallas, TX.
  • Kusminski C; Sam and Ann Barshop Institute for Longevity and Aging Studies, University of Texas Health Science Center, San Antonio, TX.
  • An Z; Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center at Houston, Houston, TX.
  • Elmquist JK; Division of Endocrinology, Department of Medicine, University of Texas Health Science Center, San Antonio, TX.
  • Scherer PE; Touchstone Diabetes Center, The University of Texas Southwestern Medical Center, Dallas, TX.
Diabetes ; 73(2): 197-210, 2024 Feb 01.
Article en En | MEDLINE | ID: mdl-37935033
ABSTRACT
Partial leptin reduction can induce significant weight loss, while weight loss contributes to partial leptin reduction. The cause-and-effect relationship between leptin reduction and weight loss remains to be further elucidated. Here, we show that FGF21 and the glucagon-like peptide 1 receptor (GLP-1R) agonist liraglutide rapidly induced a reduction in leptin. This leptin reduction contributed to the beneficial effects of GLP-1R agonism in metabolic health, as transgenically maintaining leptin levels during treatment partially curtailed the beneficial effects seen with these agonists. Moreover, a higher degree of leptin reduction during treatment, induced by including a leptin neutralizing antibody with either FGF21 or liraglutide, synergistically induced greater weight loss and better glucose tolerance in diet-induced obese mice. Furthermore, upon cessation of either liraglutide or FGF21 treatment, the expected immediate weight regain was observed, associated with a rapid increase in circulating leptin levels. Prevention of this leptin surge with leptin neutralizing antibodies slowed down weight gain and preserved better glucose tolerance. Mechanistically, a significant reduction in leptin induced a higher degree of leptin sensitivity in hypothalamic neurons. Our observations support a model that postulates that a reduction of leptin levels is a necessary prerequisite for substantial weight loss, and partial leptin reduction is a viable strategy to treat obesity and its associated insulin resistance.
Asunto(s)

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Leptina / Liraglutida Límite: Animals Idioma: En Revista: Diabetes Año: 2024 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Leptina / Liraglutida Límite: Animals Idioma: En Revista: Diabetes Año: 2024 Tipo del documento: Article